Proportions within biologic (Omalizumab or Mepolizumab, N= 167)
cohort |
|
|
|
|
|
|
(%, n/N) |
Proportions within biologic (Omalizumab or
Mepolizumab, N= 167) cohort |
|
|
|
|
|
(%, n/N) |
17.4% (29/167) |
17.4% (29/167) |
34.7% (58/167) |
23.4% (39/167) |
24.6% (41/167) |
|
Distribution within
respective biologic group |
|
|
|
|
|
|
(%, n/N), (A) |
Omalizumab, N=105 |
15.2% (16/105) |
15.2% (16/105) |
44.8% (47/105) |
18.1% (19/105) |
21.9% (23/105) |
|
Mepolizumab, N=62 |
21.0% (13/62) |
21.0% (13/62) |
17.7% (11/62) |
32.3% (20/62) |
29.0% (18/62) |
Biologic response within each phenotype (%, n/N) † |
Omalizumab responder (B) |
100% (16/16) |
100% (16/16) |
80.9%
(38/47) |
94.4% (17/18) |
91.3% (21/23) |
|
Mepolizumab responder (C) |
69.2% (9/13) |
69.2% (9/13) |
70%
(7/10) |
80% (16/20) |
73.3% (11/15) |
P-values |
P-values |
A |
0.004 |
0.004 |
0.004 |
0.004 |
|
|
B |
0.135 |
0.135 |
0.135 |
0.135 |
|
|
C |
0.893 |
0.893 |
0.893 |
0.893 |